Clinical Trials
20 trialsNCT07007559 2026-06-05
ASPEN-09-03
ALX Oncology Inc.
Phase 2 Recruiting
NCT06875128 2026-06-01
DELUMA
Delcath Systems Inc.
Phase 2 Recruiting
NCT05458674 2026-04-03
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
Criterium, Inc.
Phase 2 Recruiting
NCT06449222 2026-02-25
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
BioNTech SE
Phase 2 Active not recruiting
NCT00879086 2023-06-22
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT01104155 2023-06-22
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
Eisai Inc.
Phase 2 Completed
NCT01268150 2023-06-22
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT01269346 2023-06-22
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT01439282 2023-06-22
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT03441360 2022-10-05
Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
Eisai Inc.
Phase 2 Completed
NCT01328249 2019-08-20
Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT02481050 2018-11-15
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT00413192 2017-04-26
E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma
Eisai Inc.
Phase 2 Completed
NCT01427933 2017-02-06
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01458249 2016-03-28
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)
Eisai Inc.
Phase 2 Completed
NCT00246090 2014-07-14
A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine
Eisai Inc.
Phase 2 Completed
NCT00278993 2014-07-14
Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy
Eisai Inc.
Phase 2 Completed
NCT00965523 2013-08-15
Study of E7389 for Advanced or Metastatic Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT00097721 2013-04-22
A Study of E7389 in Advanced/Metastatic Breast Cancer Patients
Eisai Inc.
Phase 2 Completed
NCT00100932 2012-03-27
Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy
Eisai Inc.
Phase 2 Completed